An estimated 42.5 million Americans are infected with at least one type of HPV that can cause disease, including cancers and genital warts. When you count all HPV types, that number climbs to over 77 million. About 13 million new infections occur every year, making HPV the most common sexually transmitted infection in the United States by a wide margin.
Overall Prevalence by the Numbers
Among adults aged 15 to 59, roughly 40% are infected with at least one HPV type at any given time. That figure includes both high-risk strains (the ones linked to cancer) and low-risk strains that may cause warts or no symptoms at all. About 22% of adults in that age range carry a disease-associated HPV type, meaning one that can lead to precancerous changes, cancer, or genital warts.
These numbers come from national surveys that test participants directly for HPV DNA, not from doctor visits or self-reports. Because most people with HPV never develop symptoms, the true scope of infection is invisible without this kind of testing.
Infection Rates by Sex and Age
Men are slightly more likely than women to carry genital HPV. Among adults aged 18 to 59, genital HPV prevalence is 45.2% in men compared to 39.9% in women. For high-risk genital strains specifically, 25.1% of men test positive versus 20.4% of women.
The gap is even wider for oral HPV. About 11.5% of men carry oral HPV compared to 3.3% of women. For high-risk oral strains, the numbers are 6.8% and 1.2%, respectively. This difference helps explain why oropharyngeal cancers (cancers of the throat and base of the tongue) are far more common in men.
Infection rates peak in younger age groups, largely because younger adults are more likely to encounter HPV for the first time. But HPV is not limited to any one age bracket. Adults in their 40s and 50s still carry the virus at meaningful rates.
Most Infections Clear on Their Own
An HPV diagnosis is not necessarily a long-term sentence. Between 80% and 90% of HPV infections are transient, meaning your immune system clears them within about 24 months without treatment. The remaining 10% to 20% become persistent infections, and it’s this smaller group that carries the real health risk. Persistent infection with a high-risk strain is the prerequisite for HPV-related cancer, but even among persistent infections, cancer is not inevitable.
HPV and Cancer Risk
About 39,300 cancers per year in the United States are caused by HPV, out of roughly 49,900 cancers that occur in body sites where HPV is commonly found. The breakdown by cancer type:
- Oropharyngeal (throat): 16,000 cases per year, the single largest category. About 13,600 of those are in men.
- Cervical: 11,100 cases per year. HPV causes 91% of all cervical cancers.
- Anal: 7,600 cases per year, split roughly two-thirds female and one-third male.
- Vulvar: 3,000 cases per year.
- Penile: 900 cases per year.
- Vaginal: 700 cases per year.
HPV types 16 and 18 are the most dangerous. About 3.9% of women in the general population carry cervical HPV 16 or 18 at any given time. While that sounds like a small percentage, it translates to millions of women, and these two strains are responsible for the majority of HPV-related cancers.
Vaccination Has Sharply Reduced Infections
HPV vaccination was introduced in 2006, and its impact on infection rates has been dramatic. Among females aged 14 to 19, prevalence of the four HPV types targeted by the original vaccine dropped 88%, falling from 11.5% before the vaccine era to just 1.1% by 2015 to 2018. Among women aged 20 to 24, the decline was 81%, from 18.5% down to 3.3%.
What’s especially striking is the protection that extends to unvaccinated individuals through herd immunity. Among sexually experienced teenage girls who were not vaccinated, infection with vaccine-targeted strains still dropped 87%. This means fewer people carrying the virus translates to fewer opportunities for transmission across the board.
The downstream effects are showing up in cancer screening data. Among women aged 20 to 24 who were screened for cervical cancer, rates of precancerous cervical lesions dropped 79% between 2008 and 2022. Among women aged 25 to 29, the more advanced precancerous lesions dropped 37%. As of 2023, about 76.8% of adolescents aged 13 to 17 had received at least one dose of HPV vaccine, though that coverage rate has plateaued in recent years.
How HPV Screening Works
For cervical cancer prevention, screening guidelines focus on women because there is no approved HPV screening test for men. Women aged 21 to 29 are recommended to get a Pap test every three years. HPV testing is not recommended in this younger group because infections are so common and so likely to clear on their own that a positive result would lead to unnecessary follow-up.
Starting at age 30, you have more options: a Pap test every three years, an HPV test alone every five years, or both tests together every five years. The shift to allowing HPV testing at this age reflects the fact that a persistent HPV infection in your 30s or older is more clinically meaningful than one in your early 20s. Screening is generally recommended through age 65 for women with a history of normal results.
There is no routine screening test for oral HPV or for HPV in men. Most HPV-related cancers in men, particularly throat cancers, are typically detected through symptoms like a persistent lump in the neck, difficulty swallowing, or a sore throat that doesn’t resolve.